News Industry News CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI October 17, 2020
News Industry News CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial June 01, 2020
News Industry News Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES® and Market Standard Xience V® Coronary Stent February 24, 2016
News Industry News Plaque Modification With Scoring Balloon Improves Angiographic Outcomes In Patients Treated With A Drug-Coated Balloon For Drug-Eluting Stent Restenosis October 14, 2015
News Industry News EuroPCR Late-Breaking Clinical Trials: MiStent SES® Shows Clinical Superiority over Market-Leader Xience V in Propensity Analysis at One and Three Years Post-Treatment May 19, 2015